TY - JOUR T1 - Optimal COVID-19 quarantine and testing strategies JF - medRxiv DO - 10.1101/2020.10.27.20211631 SP - 2020.10.27.20211631 AU - Chad R. Wells AU - Jeffrey P. Townsend AU - Abhishek Pandey AU - Seyed M. Moghadas AU - Gary Krieger AU - Burton Singer AU - Robert H. McDonald AU - Meagan C. Fitzpatrick AU - Alison P. Galvani Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/27/2020.10.27.20211631.abstract N2 - As economic woes of the COVID-19 pandemic deepen, strategies are being formulated to avoid the need for prolonged stay-at-home orders, while implementing risk-based quarantine, testing, contact tracing and surveillance protocols. Given limited resources and the significant economic, public health, and operational challenges of the current 14-day quarantine recommendation, it is vital to understand if shorter but equally effective quarantine and testing strategies can be deployed. To quantify the probability of post-quarantine transmission upon isolation of a positive test, we developed a mathematical model in which we varied quarantine duration and the timing of molecular tests for three scenarios of entry into quarantine. Specifically, we consider travel quarantine, quarantine of traced contacts with an unknown time if infection, and quarantine of cases with a known time of exposure. With a one-day delay between test and result, we found that testing on exit (or entry and exit) can reduce the duration of a 14-day quarantine by 50%, while testing on entry shortened quarantine by at most one day. Testing on exit more effectively reduces post-quarantine transmission than testing upon entry. Furthermore, we identified the optimal testing date within quarantines of varying duration, finding that testing on exit was most effective for quarantines lasting up to seven days. As a real-world validation of these principles, we analyzed the results of 4,040 SARS CoV-2 RT-PCR tests administered to offshore oil rig employees. Among the 47 positives obtained with a testing on entry and exit strategy, 16 cases that previously tested negative at entry were identified, with no further cases detected among employees following quarantine exit. Moreover, this strategy successfully prevented an expected nine offshore transmission events stemming from cases who had tested negative on the entry test, each one a serious concern for initiating rapid spread and a disabling outbreak in the close quarters of an offshore rig. This successful outcome highlights that appropriately timed testing can make shorter quarantines more effective, thereby minimizing economic impacts, disruptions to operational integrity, and COVID-related public health risks.Competing Interest StatementJTP, GK,BS,RHM,SMM, APG received funding from the company who collected and provided dataFunding StatementJ.P.T. gratefully acknowledges funding from the National Science Foundation grant CCF 1918656, the Elihu endowment, Notsew Orm Sands Foundation, and BHP. G.K., B.S., and R.H.M acknowledge funding from BHP. S.M.M. acknowledges support from the Canadian Institutes of Health Research (grant OV4-170643; Canadian 2019 Novel Coronavirus Rapid Research), the Natural Sciences and Engineering Research Council of Canada, and BHP. A.P.G. gratefully acknowledges funding from NIH UO1-GM087719, the Burnett and Stender families' endowment, the Notsew Orm Sands Foundation, and BHP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB Approval from the Office of Research Ethics (ORE) at York University, Toronto ON, Canada Certificate #: 2020-323 (Approval Document can be provided if requested)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe number of positive tests and tests conducted at the two regions quarantining the crew members heading offshore are presented in Fig. 2, with other data used in the analysis referenced in Table S1 and in the Methods. ER -